Fri, Jul 11, 2014, 12:08 PM EDT - U.S. Markets close in 3 hrs 52 mins

Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • phakosurgeon phakosurgeon Jun 25, 2013 5:59 PM Flag

    Did I miss something?

    According to the latest presentation, AEZS is actively looking to partner for a diagnostic test for 108. Does anyone know what happened to their collaboration with Ventana, announced with such fanfare over a year ago? Seems to me dissolving that partnership would definitely be a "material even" and should have been disclosed. Did I miss this announcement?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Loo at inclusion criteria for patients in phase 3 study:
      Inclusion Criteria:
      1.Women ≥ 18 years of age
      2.Histologically confirmed endometrial cancer
      3.Advanced (FIGO stage III or IV), recurrent or metastatic disease.
      4.Measurable or non-measurable disease that has progressed since last treatment.
      5.Patients who have progressed after prior first line treatment with platinum/taxane based chemotherapy for advanced, recurrent or metastatic endometrial cancer.
      6.Availability of fresh or archival FFPE tumor specimens for analysis of LHRH receptor expression.
      It seems like the level of LHRH expression is not critical for inclusion but will be analyzed anyway.

    • Where did you get that info..?Slide 28 does not mean that the collaboration agreement with Ventana is over ...... does it?

      • 1 Reply to palinc2000
      • From their presentation, - next steps for 108
        " Pursue development of a companion diagnostic
        for zoptarelin doxorubicin (AEZS-108) and
        successor compounds"
        Does that sound like they already have a collaboration agreement? Also, why was there no mention of the Ventana collaboration. I would think that's a very important step for them.

        As the gang boss in Cool Hand Luke said: "What we have here is a failure to communicate"

 
AEZS
1.24+0.01(+0.81%)12:08 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.